COVIran Barekat / Barakat Pharma - LARVOL DELTA

Adverse events of special interest after vaccination with COVID-19 vaccines: a cohort event monitoring study in Iran. (PubMed, Eur J Med Res) - "We found around one AESI among every 8,000 vaccinated Iranian people. The incidence of AESIs after COVID-19 vaccines was relatively rare and the studied vaccines can be considered safe. AZD1222 had a higher incidence of AESIs. Coagulation disorders, and generalized seizure were the main and most common AESIs."

Adverse events • Journal • Cardiovascular • CNS Disorders • Complement-mediated Rare Disorders • Endocrine Disorders • Epilepsy • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease

Evaluating miscarriage incidence after COVID-19 vaccination. (PubMed, Sci Rep) - "This cohort study included 26,701 women of reproductive age (15-49) who were vaccinated with different vaccines (Sinopharm, Sputnik V, AZD1222 and CoVIran Barekat) between April 2021 and August 2022 in seven cities in Iran...In general, the miscarriage rate in women of reproductive age was 4.8 (95% CI 4.1-5.7) per 1000 women. The estimated incidence rates were not higher than expected; therefore, it can be argued that COVID - 19 vaccination with Sputnik V, Sinopharm, Barekat and AZD1222 does not increase the probability of miscarriage and the vaccines are therefore safe in this respect."

Journal • Infectious Disease • Novel Coronavirus Disease

COVID-19 VACCINATION INDUCED AUTOIMMUNE RHEUMATIC DISEASES: A SYSTEMATIC REVIEW OF CASE REPORTS (EULAR 2025) - "In 366 patients, the type of vaccine was specified in the report, which is as follows: Pfizer in 203 (55.7%), AstraZeneca in 92 (25.1%), Moderna in 38 (10.4%), Sinopharm in 8 (2.2%), CoronaVac (Sinovac) in 6 (1.6%), Covishield in 4 (1.1%), Covaxin in 4 (1.1%), Janssen & Janssen in 4 (1.1%), COVIran Barekat in 4 (1.1%) and Sputnik in 3 (0.8%) cases... This systematic review provides important insights into ARDs after COVID-19 vaccination and has significant clinical implications. Clinicians should be cautious and consider ARDs in the differential diagnosis of patients presenting with musculoskeletal or multisystem complaints after vaccination, especially nucleic acid-based vaccines."

Case report • Clinical • Review • Fatigue • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Influenza • Musculoskeletal Diseases • Musculoskeletal Pain • Novel Coronavirus Disease • Pain • Pruritus • Respiratory Diseases • Rheumatology • Rubella • Tetanus • Vasculitis

Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model. (PubMed, Sci Rep) - "Here, we investigated and compared the neutralising antibody induction of the ancestral variant-based BIV1-CovIran vaccine, the Omicron variant-based BIV1-CovIran Plus vaccine, and the novel bivalent vaccine candidate, BBIV1-CovIran, against the Omicron and ancestral Wuhan variants on the rat model...The 10 µg bivalent vaccine at three doses showed even higher neutralisation titers: the geometric mean of 388 (95% CI 242.2-621.7) against Omicron and 445.7 (95% CI 303.3-655.0) against Wuhan. It is shown that the candidate bivalent and Omicron-specific vaccines could elicit a potent immune response against both Wuhan-Hu-1 and Omicron BA.1 variants."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease

Humoral immunogenicity assessment after receiving three types of SARS-CoV-2 vaccine. (PubMed, Sci Rep) - "Anti-SARS-CoV-2 receptor-binding domain [RBD] IgG titer was compared in 3 groups, each vaccinated by available vaccines in Iran at the time: Oxford/AstraZeneca, COVIran Barekat, and Sinopharm...The comparison of results demonstrated that AstraZeneca vaccine is a superior candidate vaccine for COVID-19 vaccination out of the three. Our data also demonstrated statistically significant higher antibody titer among recipients with an infection history."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial. (PubMed, BMJ) - "A two dose regimen of the BIV1-CovIran vaccine conferred efficacy of 50.2% against symptomatic covid-19, 70.5% against severe disease, and 83.1% against critical disease. Vaccination was well tolerated, with no safety concerns raised."

Journal • P3 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Death Reporting in Breakthrough and Unvaccinated SARS-CoV-2 Infection Cases. (PubMed, Disaster Med Public Health Prep) - "These patients received 66.63% Sinopharm, 0.67% Sputnik, 0.67% COVIran Barekat, and 31.99% AstraZeneca vaccines...Equitable access to safe and effective vaccines is critical to ending the COVID-19 pandemic. As vaccine uptake increases, we observed a decrease in mortality and protection from severe forms of the disease."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system. (PubMed, BMC Infect Dis) - "Pain and fatigue were the most common reactogenicities of COVID-19 vaccination. Reactogenicities were less common after the second dose of the vaccines. The adverse effects of AZD1222 were greater than those of other vaccines."

Journal • Fatigue • Infectious Disease • Novel Coronavirus Disease • Pain

Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test negative case-control study. (PubMed, Int J Infect Dis) - "For almost all vaccines, the study was observed an increasing in Effectiveness against hospitalization and death over time."

Journal • Infectious Disease • Novel Coronavirus Disease • ERCC6

Signs, Symptoms, and Side-Effects Presented by Different Types of COVID-19 Vaccines: A Prospective Cohort Study. (PubMed, Life (Basel)) - "The Oxford AstraZeneca vaccine showed the highest incidence rate, onset, and lasting time of signs and symptoms in both doses; however, they were not life-threatening. The onset time of signs and symptoms was significantly higher for the COVIran Barekat and Oxford AstraZeneca vaccines in both the first and second doses."

Adverse events • Journal • Infectious Disease • Musculoskeletal Pain • Novel Coronavirus Disease • Pain

Introducing the recent developments in the production of various COVID-19 vaccines in Iran (IVC-MG 2022) - "The most famous Iranian Covid-19 Vaccine brands are COVIran Barekat, PastoCovac, Spikogen, Razi, and Fakhra which all the, have more than 80% efficiency according to recent research and national statistics and have been welcomed by the people themselves...In this speech, we are going to talk about the types of COVID 19 vaccines produced in Iran, their effectiveness, and specifications. Audience Take Away: An overview of the different types of COVID-19 vaccines produced Description of vaccines produced in Iran, their characteristics and effectiveness Investigating the relationship between coronavirus mortality statistics and the amount and types of vaccines used in different communities Steps and difficulties of producing a new vaccine in the event of an epidemic"

Infectious Disease • Novel Coronavirus Disease

Study protocol: cohort event monitoring for safety signal detection after vaccination with COVID-19 vaccines in Iran. (PubMed, BMC Public Health) - "The results of this study will be published in different articles. A live dashboard is also available for managers and policymakers. All data will be available on reasonable requests from the corresponding author.The use of the good and comprehensive guidelines provided by WHO, along with the accurate implementation of the protocol and continuous monitoring of the staff performance are the main strengths of this study which may be very useful for policymaking about COVID-19 vaccination."

Journal • Infectious Disease • Novel Coronavirus Disease

Effectiveness of Coronavirus Disease 2019 Vaccines in Preventing Infection, Hospital Admission, and Death: A Historical Cohort Study Using Iranian Registration Data During Vaccination Program. (PubMed, Open Forum Infect Dis) - "We estimated a 71.9% [95% confidence interval [CI], 70.7%-73.1%], 81.5% [95% CI, 79.5%-83.4%], 67.5% [95% CI, 59.5%-75.6%], and 86.4% [95% CI, 84.1%-88.8%] hospital admission reduction for those who received the full vaccination schedule of BBIBP-CorV (Sinopharm), ChAdOx1-S/nCoV-19 vaccine (AZD1222, Oxford-AstraZeneca), rAd26-rAd5 (Gam-COVID-Vac, Sputnik V), and BIV1-CovIran (COVIran Barekat) vaccines, respectively. A high reduction in mortality (at least 85%) was observed in all age subgroups of the fully immunized population. The pragmatic implementation of a vaccination plan including all available vaccine options in the Iranian population was associated with a significant reduction in coronavirus disease 2019 (COVID-19) detected infections as well as hospital admissions and deaths associated with COVID-19."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • ERCC6

Twitter sentiment analysis from Iran about COVID 19 vaccine. (PubMed, Diabetes Metab Syndr) - "It is worrisome that the negative sentiment toward homegrown and imported vaccines increases in Iran in some months. Since public healthcare agencies aim to increase the uptake of COVID-19 vaccines to end the pandemic, they can focus on social media such as Twitter to promote positive messaging and decrease opposing views."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Iran launches final clinical trial of domestic coronavirus vaccine (Business Standard) - "Iran has kicked off the final stage of the clinical trial of its domestic Covid-19 vaccine as two volunteers were inoculated...'Phase 1 was successfully completed with 56 volunteers, and today phases 2 and 3 of the clinical trial began,' director of the clinical trial centre at Tehran University of Medical Sciences (TUMS) Hamed Hosseini said...The receivers of the COV-Iran Barekat vaccine were two lecturers at TUMS."

Trial status • Infectious Disease • Novel Coronavirus Disease